- Home
- About
- Find staff
- Frida Westerbergh
Frida Westerbergh
-
First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the
ileum
Julia Fricke, Frida Westerbergh, Lisa McDougall, Chiara Favaretto, Emanuel Christ, Guillaume P Nicolas, Susanne Geistlich, Francesca Borgna, Melpomeni Fani, Peter Bernhardt, Nicholas P van der Meulen, Cristina Müller, Roger Schibli, Damian Wild
European Journal of Nuclear Medicine and Molecular Imaging - 2024 -
Demonstrating the Quantitative Potential of Terbium-161 SPECT/CT Imaging: An Anthropomorphic Phantom
Study
Frida Westerbergh, Nicholas van der Meulen, Cristina Müller, Andreas Grings, Philipp Ritt, Peter Bernhardt
Eur J Nucl Med Mol Imaging, Vol 50, Suppl 1 (2023), p. 38. - 2023 -
Deep Learning Denoising of 177Lu-PSMA Triple-Bed SPECT Using Clinical 68Ga PET/CT Images as Digital
Phantoms
Frida Westerbergh, Tobias Rydén, Martijn van Essen, Jon Kindblom, Peter Bernhardt
J Nucl Med, Vol 64, Suppl 1 (2023), P909 - 2023 -
Usefulness and limitations of various detector systems for estimation of I-131 activity in humans after an RN
event
Martin Hjellström, Frida Westerbergh, Eva Forssell-Aronsson, Mats Isaksson
European Radiation Protection Week (ERPW), 9-13 October 2023, Dublin, Ireland - 2023 -
Patient-Specific Kidney Recovery Coefficients May Increase Dosimetry Accuracy of (177)Lu-Radiopharmaceutical
Treatments
Frida Westerbergh, Tobias Rydén, Jehangir Khan, Martijn van Essen, Johanna Svensson, Joseph Grudzinski, Peter Bernhardt
Journal of Nuclear Medicine, June 2022; Volume 63, Issue Supplement 2 - 2022 -
Exploring the Quantitative Impact of Non-Uniformities in SPECT-Imaging With
(161)Tb
Frida Westerbergh, Tobias Rydén, Martijn van Essen, Nicholas van der Meulen, Cristina Müller, Peter Bernhardt
European Journal of Nuclear Medicine and Molecular Imaging (2022) 49 (Suppl 1): s.265-66 - 2022